Suzetrigine – A Novel Analgesic Emerges

Kyle J. Kramer

doi:10.2344/editorial_72_2

journal article Jun 01, 2025

Suzetrigine – A Novel Analgesic Emerges

Kyle J. Kramer

Anesthesia Progress Vol. 72 No. 2 pp. 63-64 · American Dental Society of Anesthesiology (ADSA)

View at Publisher Save 10.2344/editorial_72_2

Topics

No keywords indexed for this article. Browse by subject →

References

12

[1]

Hameed S. Na(v)1.7 and Na(v)1.8: Role in the pathophysiology of pain. Mol Pain. 2019;15:1744806919858801. doi:10.1177/1744806919858801

[2]

Ghovanloo MR, Tyagi S, Zhao P, Waxman SG. Nav1.8, an analgesic target for nonpsychotomimetic phytocannabinoids. Proc Natl Acad Sci USA. 2025;122(4):e2416886122. doi:10.1073/pnas.2416886122

[3]

Ganatra RB. Suzetrigine, a new nonopioid pain medication, gains U.S. FDA approval. Massachusetts Medical Society; 2025. Accessed April 25, 2025. https://www.jwatch.org/na58647/2025/04/08/suzetrigine-new-nonopioid-pain-medication-gains-us-fda

[4]

Meara K. What pharmacists need to know about suzetrigine for pain management. 2025. Accessed April 25, 2025. https://www.drugtopics.com/view/what-pharmacists-need-to-know-about-suzetrigine-for-pain-management

[5]

Grossi G. Suzetrigine: first-in-class nonopioid pain therapy is approved by FDA. 2025. Accessed April 25, 2025. https://www.ajmc.com/view/suzetrigine-the-first-non-opiate-pain-therapy-is-fda-approved

[6]

DA approves novel non-opioid treatment for moderate to severe acute pain. US Food & Drug Administration, 2025. Accessed April 25, 2025. https://www.fda.gov/news-events/press-announcements/fda-approves-novel-non-opioid-treatment-moderate-severe-acute-pain

[7]

Hameed S. Na(v)1.7 and Na(v)1.8: Role in the pathophysiology of pain. Mol Pain. 2019;15:1744806919858801. doi:10.1177/1744806919858801

[8]

Ghovanloo MR, Tyagi S, Zhao P, Waxman SG. Nav1.8, an analgesic target for nonpsychotomimetic phytocannabinoids. Proc Natl Acad Sci USA. 2025;122(4):e2416886122. doi:10.1073/pnas.2416886122

[9]

Ganatra RB. Suzetrigine, a new nonopioid pain medication, gains U.S. FDA approval. Massachusetts Medical Society; 2025. Accessed April 25, 2025. https://www.jwatch.org/na58647/2025/04/08/suzetrigine-new-nonopioid-pain-medication-gains-us-fda

[10]

Meara K. What pharmacists need to know about suzetrigine for pain management. 2025. Accessed April 25, 2025. https://www.drugtopics.com/view/what-pharmacists-need-to-know-about-suzetrigine-for-pain-management

[11]

Grossi G. Suzetrigine: first-in-class nonopioid pain therapy is approved by FDA. 2025. Accessed April 25, 2025. https://www.ajmc.com/view/suzetrigine-the-first-non-opiate-pain-therapy-is-fda-approved

[12]

DA approves novel non-opioid treatment for moderate to severe acute pain. US Food & Drug Administration, 2025. Accessed April 25, 2025. https://www.fda.gov/news-events/press-announcements/fda-approves-novel-non-opioid-treatment-moderate-severe-acute-pain

Metrics

0

Citations

12

References

Details

Published: Jun 01, 2025
Vol/Issue: 72(2)
Pages: 63-64

Authors

K

Kyle J. Kramer

Editor-in-Chief, Anesthesia Progress

Cite This Article

Kyle J. Kramer (2025). Suzetrigine – A Novel Analgesic Emerges. Anesthesia Progress, 72(2), 63-64. https://doi.org/10.2344/editorial_72_2

Suzetrigine – A Novel Analgesic Emerges

You May Also Like